Metastatic castrate-resistant prostate cancer: dawn of a new age of management
BJU International, 05/10/2012Masson S et al.
With current and forthcoming developments in the treatment of metastatic castrate–resistant prostate cancer post–docetaxel, the authors are embarking on an age of potential ‘chronic’ management of this disease. It is hoped that the survival benefits associated with the various treatments, cytotoxic, hormonal and immunotherapeutic, will prove to be additive, providing a multimodal continuum of care. If so, it will be necessary to determine the optimal sequence and timing of the new treatments.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.